Literature DB >> 11948007

Interaction between carbamazepine, zonisamide and voltage-sensitive Ca2+ channel on acetylcholine release in rat frontal cortex.

Gang Zhu1, Motohiro Okada, Takuya Murakami, Yuko Kawata, Akihisa Kamata, Sunao Kaneko.   

Abstract

To clarify the mechanisms of action of antiepileptic drugs (AEDs), carbamazepine (CBZ) and zonisamide (ZNS), on exocytosis mechanisms, the present study determined the concentration-dependent action of CBZ and ZNS, as well as the interaction between these AEDs and voltage-sensitive Ca(2+) channel (VSCC) activity on basal, Ca(2+)- and K(+)-evoked acetylcholine (ACh) release in frontal cortex of freely moving rat using in vivo microdialysis. Perfusion with therapeutic-relevant concentrations of CBZ and ZNS increased basal ACh release, which was regulated by N-type VSCC predominantly and P-type VSCC weakly, whereas supratherapeutic-relevant concentrations of these AEDs reduced this release. The 3.4 mM Ca(2+)-evoked release, which was regulated by N-type VSCC selectively, but not by P-type VSCC, was increased by therapeutic-relevant concentrations of CBZ and ZNS, whereas this release was reduced by supratherapeutic-relevant concentrations of them. The 50 mM K(+)-evoked release, which was regulated by P-type VSCC predominantly and N-type VSCC weakly, was decreased by CBZ and ZNS, in a concentration-dependent manner. These findings indicate that the interplay between enhancement of basal ACh release and reduction of depolarization-related ACh release in the frontal cortex are at least partially involved in a common mechanism of antiepileptic action between CBZ and ZNS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948007     DOI: 10.1016/s0920-1211(02)00015-3

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  8 in total

Review 1.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  The effects of postnatal alcohol exposure and galantamine on the context pre-exposure facilitation effect and acetylcholine efflux using in vivo microdialysis.

Authors:  Amy E Perkins; Jim R Fadel; Sandra J Kelly
Journal:  Alcohol       Date:  2015-02-25       Impact factor: 2.405

Review 3.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 4.  Low threshold T-type calcium channels as targets for novel epilepsy treatments.

Authors:  Kim L Powell; Stuart M Cain; Terrance P Snutch; Terence J O'Brien
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

5.  Zonisamide attenuates MPP+-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells.

Authors:  Vedat Ali Yürekli; Semih Gürler; Mustafa Nazıroğlu; Abdülhadi Cihangir Uğuz; Hasan Rifat Koyuncuoğlu
Journal:  Cell Mol Neurobiol       Date:  2012-11-15       Impact factor: 5.046

6.  Amantadine Combines Astroglial System Xc- Activation with Glutamate/NMDA Receptor Inhibition.

Authors:  Tomosuke Nakano; Toshiki Hasegawa; Dai Suzuki; Eishi Motomura; Motohiro Okada
Journal:  Biomolecules       Date:  2019-05-17

7.  Cytisine Exerts an Anti-Epileptic Effect via α7nAChRs in a Rat Model of Temporal Lobe Epilepsy.

Authors:  Jing-Jun Zheng; Teng-Yue Zhang; Hong-Tao Liu; Ze-Xin Huang; Jing-Mei Teng; Jing-Xian Deng; Jia-Gui Zhong; Xu Qian; Xin-Wen Sheng; Ji-Qiang Ding; Shu-Qiao He; Xin Zhao; Wei-Dong Ji; De-Feng Qi; Wei Li; Mei Zhang
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

8.  Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.

Authors:  Shin-Ichi Ueno; Shinji Saiki; Motoki Fujimaki; Haruka Takeshige-Amano; Taku Hatano; Genko Oyama; Kei-Ichi Ishikawa; Akihiro Yamaguchi; Shuko Nojiri; Wado Akamatsu; Nobutaka Hattori
Journal:  Cells       Date:  2018-12-29       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.